Systematic Financial Management LP raised its holdings in shares of Amedisys Inc (NASDAQ:AMED) by 12.9% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 15,450 shares of the health services provider’s stock after acquiring an additional 1,765 shares during the period. Systematic Financial Management LP’s holdings in Amedisys were worth $1,904,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of AMED. Financial Gravity Companies Inc. bought a new stake in shares of Amedisys during the fourth quarter valued at approximately $50,000. First Hawaiian Bank increased its position in shares of Amedisys by 45.6% during the fourth quarter. First Hawaiian Bank now owns 415 shares of the health services provider’s stock valued at $49,000 after acquiring an additional 130 shares in the last quarter. Meeder Asset Management Inc. increased its position in shares of Amedisys by 107.4% during the fourth quarter. Meeder Asset Management Inc. now owns 477 shares of the health services provider’s stock valued at $56,000 after acquiring an additional 247 shares in the last quarter. Captrust Financial Advisors increased its position in shares of Amedisys by 161.8% during the fourth quarter. Captrust Financial Advisors now owns 597 shares of the health services provider’s stock valued at $70,000 after acquiring an additional 369 shares in the last quarter. Finally, Group One Trading L.P. bought a new stake in shares of Amedisys during the fourth quarter valued at approximately $90,000. Institutional investors and hedge funds own 91.71% of the company’s stock.

Shares of Amedisys stock opened at $110.75 on Thursday. The firm has a market cap of $3.61 billion, a PE ratio of 30.51, a price-to-earnings-growth ratio of 1.40 and a beta of 1.33. Amedisys Inc has a 1-year low of $71.34 and a 1-year high of $140.91. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.91 and a current ratio of 0.91.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Tuesday, April 30th. The health services provider reported $1.11 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.89 by $0.22. The business had revenue of $467.34 million for the quarter, compared to analysts’ expectations of $460.83 million. Amedisys had a net margin of 7.14% and a return on equity of 28.25%. The company’s revenue was up 17.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.79 EPS. As a group, equities analysts expect that Amedisys Inc will post 4.08 EPS for the current fiscal year.

In related news, COO Christopher Gerard sold 2,500 shares of Amedisys stock in a transaction on Monday, March 11th. The shares were sold at an average price of $118.96, for a total transaction of $297,400.00. Following the transaction, the chief operating officer now owns 25,731 shares in the company, valued at approximately $3,060,959.76. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jeffrey A. Rideout sold 1,411 shares of Amedisys stock in a transaction on Monday, March 4th. The shares were sold at an average price of $121.58, for a total transaction of $171,549.38. Following the transaction, the director now owns 4,557 shares in the company, valued at approximately $554,040.06. The disclosure for this sale can be found here. Insiders have sold a total of 18,281 shares of company stock worth $2,160,243 in the last quarter. Corporate insiders own 2.90% of the company’s stock.

Several equities research analysts recently weighed in on the stock. BidaskClub raised shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 14th. Benchmark downgraded shares of Amedisys from a “buy” rating to a “hold” rating and set a $136.64 price target for the company. in a research report on Tuesday, February 5th. ValuEngine raised shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 4th. Zacks Investment Research raised shares of Amedisys from a “hold” rating to a “buy” rating and set a $151.00 price target for the company in a research report on Thursday, February 7th. Finally, Barclays raised their price target on shares of Amedisys from $115.00 to $120.00 and gave the company an “equal weight” rating in a research report on Thursday, March 21st. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $125.90.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://theolympiareport.com/2019/05/16/amedisys-inc-amed-shares-bought-by-systematic-financial-management-lp.html.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Featured Story: What is the Coverage Ratio?

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.